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Recent observations have shown that
Drm, a member the Dan family of bone
morphogenic protein (BMP) antagonists,
induces endothelial cell (EC) sprouting in
vitro and angiogenesis in vivo by interact-
ing with signaling EC receptors in a BMP-
independent manner. Here, recombinant
Drm (rDrm) up-regulates angiopoientin-1
(Ang-1) expression in EC without affect-
ing Ang-2 and Tie-2 receptor expression.
Ang-1 up-regulation is mediated by the
activation of the transcription factor NF-
!B. Specific inhibition of Ang-1 activity by
anti–Ang-1 antibodies, soluble Tie-2 re-
ceptor, or Ang-1 siRNA transfection sig-
nificantly reduced the rDrm-mediated
sprouting of EC in three-dimensional fi-
brin and type I collagen gels. In addition,
Ang-1 antagonists inhibited the angio-
genic activity exerted by rDrm in the
chick embryo chorioallantoic membrane.
Taken together, the data indicate that the
proangiogenic activity of Drm is mediated
by the activation of an Ang-1–dependent
autocrine loop of stimulation in EC.
(Blood. 2008;112:1154-1157)
Introduction
The angiopoietin/Tie receptor system, which consists of 4
angiopoietin (Ang) ligands and the Tie-1 and Tie-2 receptors,
plays a nonredundant role in embryonic vascularization and
tumor angiogenesis.1,2 An autocrine Ang-1/Tie-2 axis modulates
blood vessel plasticity and contributes to vascular maintenance.
Accordingly, Ang-1 enhances survival, migration, and network
formation of endothelial cells (ECs) in vitro3 and induces
neovascularization in vivo.4,5
Drm, a member the Dan family of bone morphogenic protein
(BMP) antagonists,6,7 interacts with signaling EC receptors in a
BMP-independent manner.8 The productive interaction stimulates
EC sprouting and migration in vitro and induces angiogenesis in
vivo.8 Drm is overexpressed in human cancers by tumor and
stromal cells, thus suggesting that Drm may contribute to tumor
neovascularization.8-10
Here, we investigated the role of the Ang/Tie-2 system in
mediating the angiogenic activity of Drm. The results demonstrate
that Drm up-regulates Ang-1 expression in EC via activation of the
transcription factor NF-!B. This leads to an autocrine loop of
stimulation that mediates Drm-induced EC sprouting in vitro and
angiogenesis in vivo.
Methods
Cell cultures
Approval for these studies was obtained from the Ethical Committee of the
School of Medicine of the University of Brescia. Subcutaneous murine
microvascular EC (SIE cells) and vascular endothelial growth factor
(VEGF) receptor-2–transduced murine aortic EC (VEGFR2-MAE cells)
were cultured in DMEM supplemented with 10% calf serum (Invitrogen,
Carlsbad, CA). Human umbilical vein ECs (HUVECs) were grown as
described.11 ECs were transfected (70%-80% efficiency) with siRNAs
using the SiRNA Transfection Reagent (Santa Cruz Biotechnology, Santa
Cruz, CA) according to the manufacturer’s instructions.
Western blotting
Western blotting was performed according to standard procedures on the
conditioned media (0.5 mL), total cell lysates (20 "g), nuclear extracts
(5 "g), and cytoplasmic fractions (10 "g) from serum-starved EC cultures
stimulated with 50 ng/mL of recombinant Drm (rDrm, R&D Systems,
Minneapolis, MN).
Electrophoretic mobility shift assay
Nuclear extracts (2 "g) were incubated with biotin-labeled NF-!B double-
stranded DNAoligonucleotide probe (5#-AGTTGAGGGGACTTTCCCAGGC)
according to LightShift Chemiluminescent EMSA Kit instructions (Pierce,
Rockford, IL) and analyzed on a native 6% polyacrylamide gel.
EC sprouting
Fibrin gel and type I collagen gel invasion assays were performed on
VEGFR2-MAE and HUVEC cell aggregates, respectively.12,13 In addi-
tion, HUVEC cell aggregates were immunostained with anti–Ang-1
antibodies (Santa Cruz Biotechnology) and analyzed under a confocal
laser microscope.
Artery ring assay
One-millimeter human umbilical artery rings were embedded in fibrin gel14
and cultured in human EC medium SFM (Invitrogen) with different stimuli.
After 3 days, EC sprouts were counted under an inverted microscope at
$10 magnification.
Gene expression analysis
cDNA was generated from total RNA using the MMLV-RT kit (Invitrogen).
Reverse-transcribed polymerase chain reaction (RT-PCR) was performed
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using murine specific primers for Ang-1 (NM_009640: 5#-TCATGCTAA-
CAGGAGGTTGGT-3#; 5#-ATGGTGGTGGAACGTAAGGA-3#); Ang-2
(NM_007426: 5#-TCGGGAGCCCTCTGGGAGAGTACT-3#; 5#-AGC-
GAATGCGCCTCGTTGC-3#); !-actin (NM_009073: 5#-CGTAAAGAC-
CTCTATGCCAACA-3#; 5#-CCACCGATCCACACAGAGTA-3#).
Chick embryo chorioallantoic membrane assay
Alginate beads (5 "L) containing vehicle, rDrm (100 ng/embryo), parental
or Drm-overexpressing COS cells8 (10 000 cells/embryo) were placed on
the chorioallantoic membrane (CAM) of fertilized White Leghorn chicken
eggs at day 11 of incubation.15 After 72 hours, new blood vessels
converging toward the implant were counted under a stereomicroscope at
$5 magnification.16
Results and discussion
Steady-state levels of Ang-1, Ang-2, Tie-2, and VEGF-A
transcripts were evaluated in rDrm-treated SIE cells by RT-PCR
analysis. Within 2 hours, rDrm causes the up-regulation of
Ang-1 expression without affecting the expression of Ang-2
(Figure 1A) or of Tie-2 and VEGF-A (data not shown).
Accordingly, Western blot analysis of rDrm-treated EC extracts
demonstrates an increase in the levels of cell-associated Ang-1
protein at 18 hours after stimulation (Figure 1B). The effect was
dose-dependent, maximal stimulation occurring at 50 ng/mL of
rDrm (data not shown). Secreted Ang-1 induces Tie-2 phosphor-
ylation in SIEC cells (Figure 1F) that was prevented by
neutralizing anti–Ang-1 antibodies (Figure S1, available on the
Blood website; see the Supplemental Materials link at the top of
the online article), pointing to an Ang-1/Tie-2 autocrine loop of
stimulation in Drm-activated ECs.
Proangiogenic cytokines and growth factors cause the activa-
tion of the transcription factor NF-!B.17 Immunofluorescence
and Western blot analysis demonstrate the rapid nuclear translo-
cation of the NF-!B RelA/p65 subunit in rDrm-treated ECs
paralleled by the degradation of the NF-!B inhibitor IKB%
(Figure 1C,D). Electrophoretic mobility shift assay (EMSA) of
the nuclear extracts with a NF-!B double-stranded DNA
oligonucleotide probe revealed an increase in the formation of
protein-DNA complexes 20 minutes after rDrm stimulation
(Figure 1E). Complex formation was prevented by an excess of
unlabeled NF-!B probe but not of a mutant NF-!B probe and
the presence of RelA/p65 in the complex(es) was confirmed by
EMSA supershifting (Figure S2).
NF-!B activation may cause Ang-1 induction.18 Accordingly,
inhibition of NF-!B activity by the NF-!B nuclear translocation
inhibitor SN50 or by the IkB% phosphorylation inhibitor BAY
11-7085 abrogates rDrm-mediated Ang-1 up-regulation and
release in SIE cells, thus preventing Tie-2 phosphorylation
(Figure 1F). Accordingly, RelA/p65 down-modulation by siRNA
transfection inhibits Ang-1 up-regulation (Figure S3). These
data demonstrate that Ang-1 induction by rDrm in EC is
mediated, at least in part, by NF-!B activation.
Drm stimulates EC sprouting and invasive activity.8 Ang-1
siRNA transfection, which suppresses Ang-1 up-regulation in
rDrm-treated cells, prevents rDrm-mediated sprouting of murine
EC aggregates in fibrin gel (Figure 2A) without affecting cell
survival and serum-dependent proliferation (data not shown).
No inhibition was instead exerted by Ang-1 siRNA on human
Ang-1–transfected ECs either in the absence or in the presence
of rDrm treatment (Figure S4). Similar to Ang-1 siRNA
transfection, neutralizing anti–Ang-1 antibodies affected rDrm-
Figure 1. rDrm induces Ang-1 expression in EC in a NF-!B–dependent manner.
(A) Serum-starved SIE cells were stimulated for 2, 6, 12, and 24 hours with
50 ng/mL of rDrm. At the end of incubation, total RNA was extracted and Ang-1
and Ang-2 transcripts were analyzed by semiquantitative RT-PCR. &-Actin was
used as a control. (B) Cell lysates were prepared from SIE cells stimulated for 0,
6, and 18 hours with 50 ng/mL of rDrm. Then, 20-"g aliquots were probed by
Western blotting with anti–Ang-1 antibodies (Santa Cruz Biotechnology). Uniform
loading of the gels was confirmed by incubation of the membranes with anti–focal
adhesion kinase (FAK) antibodies. (C) Serum-starved ECs were incubated for
20 minutes with 50 ng/mL of rDrm and immunostained with an anti-RelA/p65
antibody (Santa Cruz Biotechnology) followed by antirabbit FITC (Invitrogen).
Control cells show a diffuse cytoplasmic RelA/p65 immunoreactivity (top panel)
that localizes into the nucleus after rDrm stimulation (bottom panel). Analysis was
performed using a Zeiss Axiovert 200M epifluorescence microscope equipped
with a Plan-Apochromat 63$/1.4 NA oil objective. (D) SIE cells were stimulated
for 0 to 30 minutes with 50 ng/mL of rDrm. Then, nuclear (5 "g) and cytoplasmic
(10 "g) extracts were probed by Western blotting with anti-RelA/p65 and
anti-IkB% (Santa Cruz Biotechnology) antibodies, respectively. Uniform loading of
the gels was confirmed by incubation of the membranes with antihistone H3
(Santa Cruz Biotechnology) and anti-FAK antibodies, respectively. (E) Nuclear
extracts (2 "g) of SIE cells treated for 0 to 30 minutes with 50 ng/mL of rDrm were
incubated with a biotin-labeled NF-!B double-stranded DNA oligonucleotide
probe. (Left panel) The protein-DNA complexes were analyzed by EMSA onto a
native 6% polyacrylamide gel; the first lane shows the migration of the labeled
probe in the absence of nuclear extract. (Right panel) Densitometric analysis of
the protein-DNA complexes shown in the left panel; data are the mean plus or
minus SEM of 3 independent experiments. (F) SIE cells were treated for 1 hour
with NF-!B inhibitors SN50 (45 pg/mL, US Biological, Swampscott, MA) or BAY
11-7085 (5 "M; Sigma-Aldrich, St Louis, MO) before rDrm administration. After
18 hours, cell extracts were probed by Western blotting with anti-Ang-1 antibodies
(a). In addition, conditioned media from the corresponding cell cultures were
added for 10 minutes to naive serum-starved SIE cells. Then, immunoprecipita-
tion with anti–Tie-2 antibodies was performed on the cell extracts followed by
Western blotting with antiphosphotyrosine antibodies (Santa Cruz Biotechnology)
(b). Uniform loading of the gel was confirmed by incubation of the membrane
with anti–Tie-2 antibodies. Similar results were obtained in 2 independent
experiments.
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mediated EC sprouting (Figure 2A). In addition, a soluble Tie-2
receptor (sTie-2) inhibited rDrm-mediated invasion of type I
collagen matrix by HUVEC spheroids without affecting Ang-1
up-regulation, as shown by Ang-1 immunostaining (Figure 2B).
Moreover, anti–Ang-1 antibodies and sTie-2 abrogate the capac-
ity of rDrm to induce EC sprouting from fibrin-embedded
human umbilical artery rings (Figures 2C, S5A). Accordingly,
anti–Ang-1 antibodies prevent EC sprouting in a murine aorta
ring assay (data not shown). Finally, the 2 Ang-1 antagonists
significantly inhibit the angiogenic response triggered in vivo by
rDrm or by Drm-overexpressing COS cells8 on the chick embryo
CAM (Figures 2D, S5B).
Vascular homeostasis is controlled by a balanced Tie-2 signal-
ing.2 Ang-1 is constitutively expressed at low levels in adult
vasculature.2 However, proangiogenic stimuli, including nitric
oxide, hypoxia, TNF%, and VEGF, cause Ang-1 up-regulation.18-20
In addition, Ang-1 triggers neovascularization in vivo4,5 and
modulates EC sprouting and vascular network formation in vitro.3
Here, we demonstrate the capacity of the proangiogenic factor Drm
to increase Ang-1 production in murine and human ECs. Ang-1
up-regulation plays a nonredundant role in the angiogenic process
triggered by Drm. Indeed, inhibition of the Ang-1/Tie-2 autocrine
loop of stimulation by Ang-1 antagonists or by siRNA transfection
hampers Drm-mediated EC sprouting in vitro and angiogenesis in
vivo. Interestingly, Ang-1 antagonists cause also an approximately
50% inhibition of the angiogenic response triggered by VEGF-A or
fibroblast growth factor-2 in the CAM assay (S. M., unpublished
observations, January 2008), indicating that activation of the
Ang-1/Tie-2 system may represent a common step in the angio-
genic process.
Drm-induced Ang-1 up-regulation in EC is mediated, at least
in part, by activation of NF-!B. NF-!B triggers a proinflamma-
tory/proangiogenic transcription program in endothelium and
regulates the production of various angiogenic factors.17 Accord-
ingly, various NF-!B-modulated chemokines (ie, CCL2, CCL7,
CXCL1, and CXCL2) and cell adhesion molecules (ie, ICAM1
and VCAM1) are up-regulated in rDrm-treated SIE cells in
addition to Ang-1 (G.A., unpublished observations, September
2007). Interestingly, Ang-1 exerts anti-inflammatory effects.2
NF-!B-mediated Ang-1 up-regulation by Drm may represent a
negative feedback mechanism of control of the inflammatory
response during angiogenesis.
Figure 2. Ang-1 modulates the proangiogenic activity of rDrm. (A) Cell aggregates from naive VEGFR2-MAE cells (') or from VEGFR2-MAE cells transfected with
fluorescein-conjugated control siRNA (c) or 4 different Ang-1 siRNA (1-3, 3 distinct single oligonucleotides, [Qiagen, Valencia, CA]; 4, one pool of 3 different oligonucleotides,
Santa Cruz Biotechnology) were embedded in fibrin gel. Then, 50 ng/mL of rDrm was added on the top of the gel in medium containing 10 "g/mL of aprotinin. In addition, some
rDrm-treated aggregates were incubated in the presence of 1.0 "g/mL of neutralizing anti–Ang-1 antibodies or irrelevant IgGs. Formation of radially growing cell sprouts was
observed during the next 48 hours.8 Sprouts were photographed at$40 magnification with an IX51 inverted microscope equipped with a 4$/0.10 NA objective and a Camedia
C-4040 digital camera (Olympus, Melville, NY). Sprouting was quantified by computerized analysis of the digitalized images.8 Data are expressed as means plus or minus SEM
(n ( 10). * Statistically different from rDrm-treated naive cells (P ) .01, Student t test). Conditioned media from the corresponding transfectants were analyzed for Ang-1
protein content by Western blotting (inset). (B) HUVEC spheroids prepared in medium supplemented with carboxymethylcellulose were embedded in type I collagen gel and
treated with vehicle or 30 ng/mL of rDrm in the absence or in the presence of 100 ng/mL sTie-2 (Relia-Tech, Woburn, MA). After 24 hours, cell sprouts were photographed at
$200 magnification using an Axiovert 200M microscope equipped with a 20$ objective (LD A PLAN 20$/0.30PH1, Zeiss, Jena, Germany). Aggregates were fixed in 4%
paraformaldehyde, permeabilized in TBS-0.2% Triton X100, and costained with anti–Ang-1 antibodies/antirabbit Alexa594 (Invitrogen) (in red) and counterstained with
4#,6-diamidino-2-phenylindole (Sigma-Aldrich) (in blue). Images were acquired using a LSM510Meta confocal microscope equipped with objective LD A PLAN 32$/0.40PH1
and processed using the LSM software (Zeiss). (C) One-millimeter human umbilical artery rings were embedded in fibrin gel and incubated with the indicated concentrations of
rDrm in the absence or in the presence of 1.0 "g/mL of neutralizing anti-Ang-1 antibodies or 100 ng/mL of sTie-2. After 3 days, EC sprouts were counted under an IX51 inverted
microscope at $10 magnification. * Statistically different from rDrm-treated rings (P ) .01, Student t test). (D) Alginate beads containing vehicle, 100 ng of rDrm, parental
([GRAPHIC]) or Drm-overexpressing-COS cells (10 000 cells/embryo) were implanted on the top of chick embryo CAMs at day 11 of development. When indicated, pellets
contained also 1.0 "g of neutralizing anti–Ang-1 antibodies or 100 ng of sTie-2. After 72 hours, newly formed blood vessels converging toward the implant were counted in ovo
at$5 magnification using a STEMI SR stereomicroscope equipped with an objective f equal to 100 mm with adapter ring 475070 (Zeiss). Data are expressed as mean plus or
minus SEM (n ( 6-8); * Statistically different from the corresponding stimulus in the absence of any inhibitor (P ) .01, Student t test).
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